100277-27-8

Usage

Uses

Used in Pharmaceutical Industry:
2H-Thiopyran-4-methanol, tetrahydrois used as a key intermediate in the synthesis of new drugs and pharmaceutical compounds. Its unique structure and properties enable the development of innovative therapeutic agents with potential applications in treating various diseases and medical conditions.
Used in Synthetic Chemistry:
In the field of synthetic chemistry, 2H-Thiopyran-4-methanol, tetrahydroserves as a valuable building block for the creation of complex organic molecules. Its reactivity and compatibility with other chemical groups make it an essential component in the synthesis of advanced materials and specialty chemicals.
Used in Organic Synthesis:
2H-Thiopyran-4-methanol, tetrahydrois employed as a crucial intermediate in organic synthesis, allowing chemists to construct a wide range of organic compounds with diverse applications. Its unique structure and properties facilitate the formation of new chemical bonds and the synthesis of novel molecules with potential uses in various industries.
Used in Agrochemical Development:
This chemical compound is also utilized in the development of new agrochemicals, such as pesticides and herbicides. Its unique properties and reactivity contribute to the creation of innovative and effective products for agricultural applications, enhancing crop protection and yield.
Used in Material Science:
2H-Thiopyran-4-methanol, tetrahydrohas potential applications in the development of new materials with unique properties. Its incorporation into various material systems can lead to the creation of advanced materials with improved performance characteristics, such as enhanced stability, reactivity, or selectivity, for use in various industries.

InChI:InChI=1/C6H12OS/c7-5-6-1-3-8-4-2-6/h6-7H,1-5H2

Upstream product

• 856939-74-7 tetrahydro-thiopyran-4-carboxylic acid ethyl ester 
• 128094-82-6 tetrahydro-thiopyran-4-carboxylic acid methyl ester 
• 5337-03-1 tetrahydro-2H-pyran-4-carboxylic acid 
• 5382-77-4 tetrahydro-pyran-4,4-dicarboxylic acid diethyl ester 
• 89489-53-2 tetrahydro-2H-thiopyran-4-carboxylic acid 
• 50-00-0 formaldehyd 
• 281204-90-8 4-iodotetrahydro-2H-thiopyran 
• 195503-40-3 tetrahydro-2H-thiopyrane-4-carbonitrile 
• 50675-19-9 4-thianylcarbaldehyde 
• 1072-72-6 Tetrahydrothiopyran-4-one 
• 857778-39-3 4-bromo-2-(2-bromo-ethyl)-butyric acid ethyl ester 
• 128094-79-1 4-bromo-2-(2-hydroxyethyl)butyric acid 
• 128094-80-4 4-bromo-2-(2-bromoethyl)butanoic acid 
• 5337-04-2 tetrahydro-4H-pyran-4,4-dicarboxylic acid 

Downstream Products

• 50675-19-9 4-thianylcarbaldehyde 
• 473254-28-3 (1,1-dioxo-hexahydro-1-thiopyran-4-yl)-methanol 
• 928149-12-6 (1,1-dioxidotetrahydro-2H-thiopyran-4-yl)methyl 4-methylbenzenesulfonate 
• 1276056-87-1 4-(bromomethyl)thiane 

Relevant academic research and scientific papers

Photochemical Homologation for the Preparation of Aliphatic Aldehydes in Flow

Cheap and readily available aqueous formaldehyde was used as a formylating reagent in a homologation reaction with nonstabilized diazo compounds, enabled by UV photolysis of bench-stable oxadiazolines in a flow photoreactor. Various aliphatic aldehydes were synthesized along with the corresponding derivatized alcohols and benzimidazoles. No transition-metal catalyst or additive was required to affect the reaction, which proceeded at room temperature in 80 min.

Discovery of potent and orally bioavailable heterocycle-based cannabinoid CB1 receptor agonists

Novel 3-(1H-indol-3-yl)-1,2,4-oxadiazoles and -thiadiazoles were synthesized and found to be potent CB1 cannabinoid receptor agonists. The oral bioavailability of these compounds could be dramatically improved by optimization studies of the side chains attached to the indole and oxadiazole cores, leading to identification of a CB1 receptor agonist with good oral activity in a range of preclinical models of antinociception and antihyperalgesia.

Expansion of substrate scope for nitroxyl radical/copper-catalyzed aerobic oxidation of primary alcohols: A guideline for catalyst selection

Four distinctive sets of optimum nitroxyl radical/copper salt/additive catalyst combinations have been identified for accommodating the aerobic oxidation of various types of primary alcohols to their corresponding aldehydes. Interestingly, less nucleophilic catalysts exhibited higher catalytic activities for the oxidation of particular primary allylic and propargylic alcohols to give α,β-unsaturated aldehydes that function as competent Michael acceptors. The optimum conditions identified herein were successful in the oxidation of various types of primary alcohols, including unprotected amino alcohols and divalent-sulfur-containing alcohols in good-to-high yields. Moreover, N-protected alaninol, an inefficient substrate in the nitroxyl radical/ copper-catalyzed aerobic oxidation, was oxidized in good yield. On the basis of the optimization results, a guideline for catalyst selection has been established.

Radical hydroxymethylation of alkyl iodides using formaldehyde as a C1 synthon

Radical hydroxymethylation using formaldehyde as a C1 synthon is challenging due to the reversible and endothermic nature of the addition process. Here we report a strategy that couples alkyl iodide building blocks with formaldehyde through the use of photocatalysis and a phosphine additive. Halogen-atom transfer (XAT) from α-aminoalkyl radicals is leveraged to convert the iodide into the corresponding open-shell species, while its following addition to formaldehyde is rendered irreversible by trapping the transient O-radical with PPh3. This event delivers a phosphoranyl radical that re-generates the alkyl radical and provides the hydroxymethylated product.

SULFONYL-SUBSTITUTED BICYCLIC COMPOUND WHICH ACTS AS ROR INHIBITOR

Provided is a sulfonyl-substituted bicyclic compound (A) which acts as a RORγ inhibitor, said compound has good RORγ inhibitory activity and is expected to be used for treating diseases mediated by a RORγ receptor in mammals.

INDOLE DERIVATIVES

The invention relates to indole derivative having the general Formula I wherein A represents a 5-membered aromatic heterocyclic ring, wherein X1, X2 and X3 are independently selected from N, O, S and CH; Y represents CH2, O, S or SO2; R1 is H, (C1-4)-alkyl, (C1-4)alkyloxy, CN or halogen; R2, R2′, R3, R3′, R4, R4′, R5 and R5′ are independently hydrogen, (C1-4)alkyl (optionally substituted with OH) or CO—OR8; or one pair of geminal substituents R3 and R3′ or R5 and R5′ together represent a keto group, and the others are all hydrogen or (C1-4)alkyl; or R2 and R5 together represent a methylene or an ethylene bridge, and R2′, R3, R3′, R4, R4′ and R5′ are hydrogen; n is 1 or 2; R6 is H, (C1-4)alkyl (optionally substituted with OH(C1-4)alkyloxy, CO—NR9R10, CO—OR11 or 1,2,4-oxadiazol-3-yl), SO2NR12R13 or COOR14; R7 is H or halogen; R8 is (C1-4)alkyl; R9 and R10 are independently hydrogen, (C1-4)alkyl or (C3-7)cycloalkyl, the alkyl groups being optionally substituted with OH or (C1-4)alkyloxy; R11 is H or (C1-4)alkyl; R12 and R13 are independently H or (C1-4)alkyl; R14 is (C1-6)alkyl; or a pharmaceutically acceptable salt thereof, as agonists of the cannabinoid CB1 receptor, which can be used in the treatment of pain such as for example peri-operative pain, chronic pain, neuropathic pain, cancer pain and pain and spasticity associated with multiple sclerosis.

SYNERGISTIC COMBINATION FOR THE TREATMENT OF PAIN (CANNABIOID RECEPTOR AGONIST AND OPIOD RECEPTOR AGONIST)

The invention relates to a pharmaceutical dosage form comprising an analgesic combination for simultaneous or sequential use which comprises a peripherally restricted cannabinoid CB1 receptor agonist having a brain Cmax to plasma Cmax ratio of less than 0

(INDOL-3-YL)-HETEROCYCLE DERIVATIVES AS AGONISTS OF THE CANNABINOID CB1 RECEPTOR

The invention relates to indole derivative having the general Formula (I) Wherein A, X1, X2, X3, Y, R1, R2, R3 and R4 are as defined in the claims, or a pharmaceutically acceptab

Indole derivatives

Disclosed herein are indole derivatives of the formula (I) wherein each of the substitutents is given the definition as set forth in the specification and claims. Also disclosed are pharmaceutical compositions containing the indole derivatives and use of

SYNTHESIS OF OXOSULFONIUM SALTS BY THE OXIDATION OF SULFONIUM SALTS

A general synthetic method for oxosulfonium salts by oxidation of sulfonium salts with sodium perbenzoate (or sodium m-chloroperbenzoate) was developed.In case of the oxidation of aryldimethylsulfonium salts, the corresponding oxosulfonium salts (1e-h) were obtained in 64-91percent yields.Diphenylmethylsulfonium and triphenylsulfonium salts were also oxidized with sodium perbenzoate to afford the corresponding oxosulfonium salts (1i and 1j) in 75 and 58percent yields, respectively.Trialkylsulfonium salts such as trimethylsulfonium, dimethyloctylsulfonium, S-methylthiolanium, and S-methyl(pentamethylene)sulfonium salts, were also oxidized to the corresponding oxosulfonium salts (1a-d) in good yields.To clarify the reaction mechanisms, the oxidation of bicycloheptane-1-sulfonium salt (5) was investigated and found to afford oxosulfonium salt (6) in 50percent yield.A reaction mechanism involving nucleophilic attack by perbenzoate anion on the cationic sulfur atom of sulfonium salt and giving an S-O sulfurane intermediate is proposed.